THE ATTITUDE OF YOUNG PEOPLE TO SMOKING ELECTRONIC CIGARETTES, PHARMACOTHERAPY OF NICOTINE ADDICTION

DOI: https://doi.org/10.29296/25877305-2022-02-04
Issue: 
2
Year: 
2022

T. Potupchik(1), Candidate of Medical Sciences; L. Evert(2, 3), MD, Yu. Kostyuchenko(2); A.
Ilyashevich(1); M. Tkach(1) (1)V.F. Voino-Yasenetsky Krasnoyarsk State Medical University of the Ministry of
Health of the Russia (2)Federal Research Center «Krasnoyarsk Scientific Center of the Siberian Branch of the
Russian Academy of Sciences», Scientific Research Institute of Medical Problems of the North (3)N.F. Katanov
Khakass State University of the Ministry of Science and Higher Education of the Russian Federation, Abakan

A review of information on the increasing use of electronic smoking products in modern society – vapes (including electronic cigarettes – ES), their characteristics (structure, composition, mechanism of action, effect on the body) is given. The data of studies that have shown that ES, especially nicotine-containing, have numerous negative effects on many organs and tissues of vapers are presented. The results of our own research on the attitude of students to electronic cigarettes are included. It is shown that a significant part of the respondents are critical of their use, believing that ES are harmful to health, involve young people in the process of smoking and conventional cigarettes. Various strategies for the treatment of nicotine addiction (pharmacological and non-drug) are highlighted. As a pharmacological correction, the possibility of nicotine and nicotine-free pharmacological therapy is considered. It is recommended to include psychological and behavioral and alternative therapy in the arsenal of non-drug correction.
Keywords: 
smoking
electronic cigarettes
vapers
health effects
pharmacotherapy of nicotine addiction

References: 
  1. Gambarjan M.G. Vsja pravda ob elektronnyh sigaretah: Rossijskaja real'nost'. Chast' I. Elektronnye sigarety – ugroza dlja ljudej i antitabachnoj politiki v Rossii. Aktual'nost' pravovogo regulirovanija. Profilakticheskaja meditsina. 2019; 22 (5): 7–15 [Gambaryan M.G. The whole truth of electronic cigarettes: the Russian reality. Part I. Electronic cigarettes a threat to people and Tobacco control policy in Russia. Urgency for legal regulation. Profilakticheskaya Meditsina. 2019; 22 (5): 7–15 (in Russ.)]. DOI: 10.17116/profmed2019220517
  2. Gambarjan M.G., Kalinina A.M., Popovich M.V. i dr. Vsja pravda ob elektronnyh sigaretah: Rossijskaja real'nost'. Chast' III. Podderzhka zakonodatel'nogo regulirovanija elektronnyh sigaret naseleniem Rossii. Rezul'taty reprezentativnogo oprosa vzroslogo naselenija EPOHA-RF. Profilakticheskaja meditsina. 2020; 23 (1): 23–34 [Gambaryan M.G., Kalinina A.M., Popovich M.V. et al. The whole truth of Electronic cigarettes: the Russian reality. Part III. Support for legal regulations of Electronic cigarettes. Results from adult population representative survey EPOCHA-RF. Profilakticheskaya Meditsina. 2020; 23 (1): 23–34 (in Russ.)]. DOI: 10.17116/profmed20202301123
  3. Gosudarstvennyj reestr lekarstvennyh sredstv [State Register of Medicines (in Russ.)]. URL: http://sites.reformal.ru/grls.rosminzdrav.ru/
  4. Mendelevich V.D. Pol'za i vred elektronnyh sigaret skvoz' prizmu raznyh terapevticheskih metodologij. Vestnik sovremennoj klinicheskoj meditsiny. 2015; 8 (2): 62–72 [Mendelevich V.D. The benefits and harms of electronic cigarettes through the prism of different therapeutic methodologies. Bulletin of Modern Clinical Medicine. 2015; 8 (2): 62–72 (in Russ.)].
  5. Otsenka himicheskogo sostava elektronnyh sigaret. Prakticheskaja pul'monologija. 2015; 3: 77–8 [Evaluation of the chemical composition of electronic cigarettes. Practical pulmonology. 2015; 3: 77–8 (in Russ.)].
  6. Petrejkin I.Ju., Petrejkina K.S. Chemu otdaet predpochtenie molodezh': obychnym sigaretam ili elektronnym? Mezhdunarodnyj studencheskij nauchnyj vestnik. 2019; 2 [Petreykin I.Yu., Petreykina K.S. What do young people prefer: regular cigarettes or electronic ones? International Student Scientific Bulletin. 2019; 2 (in Russ.)]. Available at: https://eduherald.ru/ru/article/view?id=19587
  7. Prekraschenie potreblenija tabaka i lechenie tabachnoj zavisimosti: nauchno obosnovannye rekomendatsii. Pod red. A.K. Demina. M.: Vashington, 2013 [Cessation of tobacco use and treatment of tobacco addiction: scientifically based recommendations. Ed. A.K. Demin. M.: Washington, 2013 (in Russ.)].
  8. Skvortsova E.S., Mamchenko M.M. Kurenie elektronnyh sigaret kak mediko-sotsial'naja problema. Profilakticheskaja meditsina. 2021; 24 (8): 89–94 [Skvortsova E.S., Mamchenko M.M. Smoking electronic cigarettes as a medical and social problem. Profilakticheskaya Meditsina. 2021; 24 (8): 89–94 (in Russ.)]. DOI: 10.17116/profmed20212408189
  9. Speranskaja O.I., Smirnov B K., Bogdanov K.A. Pervichnaja i vtorichnaja terapevticheskaja rezistentnost' k nikotinzamestitel'noj terapii u lits s tabachnoj zavisimost'ju. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2013; 113 (9): 59–62 [Speranskaia O.I., Smirnov V.K., Bogdanov K.A. Primary and secondary resistance to nicotine replacement therapy in tobacco dependent patients. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2013; 113 (9): 59–62 (in Russ.)].
  10. Elektronnye sistemy dostavki nikotina i elektronnye sistemy dostavki produktov, ne javljajuschihsja nikotinom. Doklad VOZ. FCTC/COP/7/11 avgust 2016 g. [Electronic Nicotine Delivery Systems and Electronic Non-Nicotine Delivery Systems (ENDS/ENNDS) Report by WHO. FCTC/ COP/7/11 August 2016. (in Russ.)]. URL: https://www.who.int/fctc/cop/cop7/FCTC_COP_7_11_RU.pdf
  11. Elektronnye sistemy dostavki nikotina: doklad VOZ. M., 2014 [Electronic nicotine delivery systems: WHO report. M., 2014 (in Russ.)]. URL: http://apps.who.int/gb/fctc/PDF/cop6/FCTC_COP6_10-ru.pdf
  12. Adkison S.E., O’Connor R.J., Bansal-Travers M. et al. Electronic nicotine delivery systems: international tobacco control four-country survey. Am J Prev Med. 2013; 44: 207–15. DOI: 10.1016/j.amepre.2012.10.018
  13. Ahmad S., Zafar I., Mariappan N. et al. Acute pulmonary effects of aerosolized nicotine. Am J Physiol Lung Cell Mol Physiol. 2019; 316: L94–L104. DOI: 10.1152/ajplung.00564.2017
  14. Beard E., McNeill A., Aveyard P. et al. Use of nicotine replacement therapy for smoking reduction and during enforced temporary abstinence: a national survey of English smokers. Addiction. 2011; 106 (1): 197–204. DOI: 10.1111/j.1360-0443.2010.03215.x
  15. Bedell S., Wells J., Liu Q. et al. Vitexin as an active ingredient in passion flower with potential as an agent for nicotine cessation: vitexin antagonism of the expression of nicotine locomotor sensitization in rats. Pharm Biol. 2019; 57 (1): 8–12. DOI: 10.1080/13880209.2018.1561725
  16. Bowler R.P., Hansel N.N., Jacobson S. et al. Electronic Cigarette Use in US Adults at Risk for or with COPD: Analysis from Two Observational Cohorts. J Gen Intern Med. 2017; 32: 1315–22. DOI: 10.1007/s11606-017-4150-7
  17. Breland A.B., Almond L., Kienzle J. et al. Targeting tobacco in a community-based addiction recovery cohort: results from a computerized, brief, randomized intervention trial. Contemp Clin Trials. 2014; 38 (1): 113–20. DOI: 10.1016/j.cct.2014.03.008
  18. Bruijnzeel A.W. Neuropeptide systems and new treatments for nicotine addiction. Psychopharmacology (Berl). 2017; 234 (9–10): 1419–37. DOI: 10.1007/s00213-016-4513-5
  19. Bullen C., Howe C., Laugesen M. Electronic Cigarettes for Smoking Cessation: A Randomised Controlled Trial. J Vasc Surg. 2014; 59 (3): 872. DOI: 10.1016/j.jvs.2014.01.028
  20. Cahill K., Lindson-Hawley N., Thomas K.H. et al. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2016; 2016 (5): CD006103. DOI: 10.1002/14651858.CD006103.pub7
  21. Cahill K., Stevens S., Perera R. et al. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013; 2013 (5): CD009329. DOI: 10.1002/14651858.CD009329.pub2
  22. Di Matteo V., Pierucci M., Di Giovanni G., et al. The neurobiological bases for the pharmacotherapy of nicotine addiction. Curr Pharm Des. 2007; 13 (12): 1269–84. DOI: 10.2174/138161207780618920
  23. Duffney P.F., McCarthy C.E., Nogales A. et al. Cigarette smoke dampens antiviral signaling in small airway epithelial cells by disrupting TLR3 cleavage. Am J Physiol Lung Cell Mol Physiol. 2018; 314 (3): L505–L513. DOI: 10.1152/ajplung.00406.2017
  24. Etter J.-F. Electronic cigarettes: a survey of users. BMC Public Health. 2010; 10: 231. DOI: 10.1186/1471-2458-10-231
  25. Etter J.-F., Bullen C. Electronic cigarette: users profile, utilization, satisfaction and perceived efficacy. Addiction. 2011; 106 (11): 2017–28. DOI: 10.1111/j.1360-0443.2011.03505.x
  26. Fiore M.C., Jaén C.R. Treating tobacco use and dependence: 2008 Update A U.S. Public Health Service report. Am J Prev Med. 2008; 35: 158–76.
  27. Fiore M.S., Baker T.B. Treating Smokers in the Health Care Setting. N Engl J.Med. 2011; 365: 1222–31. DOI: 10.1056/NEJMcp1101512
  28. Giulietti F., Filipponi A., Rosettani G. et al. Pharmacological Approach to Smoking Cessation: An Updated Review for Daily Clinical Practice. High Blood Press Cardiovasc Prev. 2020; 27 (5): 349–62. DOI: 10.1007/s40292-020-00396-9
  29. Hammond D., Reid J.L., Rynard V.L. et al. Prevalence of vaping and smoking among adolescents in Canada, England, and the United States: repeat national cross sectional surveys. BMJ. 2019; 365: l2219. DOI: 10.1136/bmj.l2219
  30. Heydari G., Marashian M., Ebn Ahmady A. et al. Which form of nicotine replacement therapy is more effective for quitting smoking? A study in Tehran, Islamic Republic of Iran. East Mediterr Health J. 2012; 18 (10): 1005–10. DOI: 10.26719/2012.18.10.1005
  31. Houezec J.L. Role of nicotine pharmacokinetics in nicotine addiction and nicotine replacement therapy: a review. Int J Tuberc Lung Dis. 2003; 7 (9): 811–9. DOI: 10.1186/1471-2458-10-231
  32. Islam N., Rahman S. Improved treatment of nicotine addiction and emerging pulmonary drug delivery. Drug Discov Ther. 2012; 6 (3): 123–32.
  33. Marketers of electronic cigarettes should halt unproved therapy claims. World Health Organization. Accessed May 27, 2020. URL: https://www.ivyroses.com/Health/2206
  34. McNeill A., Brose L.S., Calder R. et al. Vaping in England, an evidence updates, February 2019. A report commissioned by Public Health England. London: Public Health England, 2019. Accessed September 9, 2019. URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/821179/Vaping_in_England_an_evidence_update_September_2019.pdf
  35. Middlekauff H.R. Cardiovascular impact of electronic-cigarette use. Trends Cardiovasc Med. 2019; 30 (3): 133–40. DOI: 10.1016/j.tcm.2019.04.006
  36. Ozarowski M., Mikołajczak P.Ł., Thiem B. Medicinal plants in the phytotherapy of alcohol or nicotine addiction. Implication for plants in vitro cultures. Przegl Lek. 2013; 70 (10): 869–74.
  37. Pedersen S.T., Christensen H.R., Døssing M. Treatment of nicotine addiction. Drug therapy for smoking cessation. Ugeskr Laeger. 2002; 164 (11): 1480–4.
  38. Position Statement on Electronic Cigarettes [ECs] or Electronic Nicotine Delivery Systems [ENDS], International Union Against Tuberculosis and Lung Disease, 44th Union World Conference on Lung Health, Paris, 3 November 2013. Raleigh M.D., Beltraminelli N., Fallot S. et al. Attenuating nicotine’s effects with high affinity human anti-nicotine monoclonal antibodies. PLoS One. 2021; 16 (7): e0254247. DOI: 10.1371/journal.pone.0254247
  39. Ruszkiewicz J.A., Zhang Z., Gonalves F.M. et al. Neurotoxicity of e-cigarettes. Food Chem Toxicol. 2020; 138: 111245. DOI: 10.1016/j.fct.2020.111245
  40. Sliwińska-Mossoń M., Zieleń I., Milnerowicz H. New trends in the treatment of nicotine addiction. Acta Pol Pharm. 2014; 71 (4): 525–30.
  41. Smith L.C., George O. Advances in smoking cessation pharmacotherapy: Non-nicotinic approaches in animal models. Neuropharmacology. 2020; 178: 108225. DOI: 10.1016/j.neuropharm.2020.108225
  42. Thisted T., Biesova Z., Walmacq C. et al. Optimization of the enzyme that decomposes nicotine for potential use in the treatment of nicotine addiction. BMC Biotechnol. 2019; 19 (1): 56. DOI: 10.1186/s12896-019-0551-5
  43. Uruma R. Smoking cessation for COPD. Nihon Rinsho. 2016; 74 (5): 783–8.
  44. Zhao Z., Powers K., Hu Y. et al. Engineering of a hybrid nanoparticle-based nicotine nanovaccine as a next-generation immunotherapeutic strategy against nicotine addiction: A focus on hapten density. Biomaterials. 2017; 123: 107–17. DOI: 10.1016/j.biomaterials.2017.01.038